NASDAQ:CYTK

Cytokinetics Stock Insider Trading

Healthcare > Biotechnology

Buy CYTK

*Your capital is at risk

$82.24

-2.63 (-3.10%)

At Close: Jul 13, 2026

Cytokinetics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -86.35. In total, the insiders bought 385.76K and sold 236.99K CYTK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-86.35
● Buy	385.76K shares
● Sell	236.99K shares
75% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Mar 17, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -86.35. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 07, 2026 Sell	Common Stock S-Sale	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $303.2K
Jul 07, 2026 Buy	Common Stock M-Exempt	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $27.3K
Jul 07, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $27.3K
Jul 01, 2026 Sell	Common Stock S-Sale	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	1 112 Value: $97.6K
Jul 01, 2026 Sell	Common Stock S-Sale	Blum Robert I President & CEO	CEO / President	7 500 Value: $636.9K
Jul 01, 2026 Sell	Common Stock S-Sale	Callos Andrew EVP, Chief Commercial Officer	Officer	15 000 Value: $1.29M
Jul 01, 2026 Buy	Common Stock M-Exempt	Callos Andrew EVP, Chief Commercial Officer	Officer	15 000 Value: $348.9K
Jul 01, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Callos Andrew EVP, Chief Commercial Officer	Officer	15 000 Value: $348.9K
Jul 01, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	1 112 Value: $53.9K
Jul 01, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	1 112 Value: $53.9K
Jun 29, 2026 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	188 Value: $8K
Jun 29, 2026 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	188 Value: $8K
Jun 29, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	823 Value: $36.5K
Jun 29, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	822 Value: $36.5K
Jun 29, 2026 Sell	Common Stock S-Sale	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	3 134 Value: $266.4K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	823 Value: $36.5K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	188 Value: $8K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	1 113 Value: $54.0K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	822 Value: $36.5K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	188 Value: $8K
Jun 29, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	1 113 Value: $54.0K
Jun 24, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	1 113 Value: $54.0K
Jun 24, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	9 307 Value: $412.9K
Jun 24, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	1 113 Value: $54.0K
Jun 24, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	23 370 Value: $1.13M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CYTOKINETICS

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati...

Read Full Profile Here